UConn Professors Develop Non-Opioid Pain Management Solution

• UConn professors are developing a novel approach to pain management that aims to minimize the use of opioid medications.
• Soleia Biosciences, a startup founded by the professors, is working to bring the new formulation to clinical trials.
• Preclinical trials have shown the formulation can reduce pain for over three weeks without prolonged numbing effects, potentially aiding rehabilitation.
• The innovation seeks to provide surgeons with an additional tool for post-operative pain management, addressing concerns about opioid dependency.

Two UConn professors are pioneering a new approach to pain management, aiming to reduce reliance on opioid medications. Dr. Lakshmi Nair and Dr. Yusuf Khan, professors of orthopedic surgery, have been developing a novel formulation designed to extend the effectiveness of local anesthesia while minimizing the need for opioids.

Addressing the Need for Non-Opioid Pain Relief

Opioids are commonly used for pain management but carry significant risks, including dependency and adverse side effects like grogginess and dizziness. Many patients seek alternatives due to these concerns. The professors' solution aims to provide an additional tool for surgeons to offer patients recovering from painful surgeries.

Extending the Duration of Local Anesthesia

Typical local anesthesia lasts for a short duration, ranging from two to twelve hours, limiting its effectiveness for major surgeries or chronic pain management. Nair and Khan have developed a formulation that extends the efficacy of local anesthetics, providing pain relief for over three weeks in preclinical trials. The formulation is administered via injection, similar to a typical anesthetic.

Preclinical Success and Future Clinical Trials

The formulation has demonstrated an analgesic effect, reducing pain while allowing patients to remain relatively mobile. This is crucial for rehabilitation after major operations or for managing chronic pain. Soleia Biosciences, the startup founded by Nair and Khan, is focused on bringing the formulation to clinical trials.

From Lab to Clinic: Soleia Biosciences

Nair and Khan launched Soleia Biosciences to bridge the gap between research and clinical application. They participated in the National Science Foundation I-Corps program and UConn's Connecticut Center for Entrepreneurship & Innovation Summer Fellowship Accelerator. Their company won first place in the Wolff New Venture Competition, securing $30,000 to connect with experts and initiate clinical trials.

Navigating the Challenges of Clinical Translation

While preclinical studies have shown promising results, the professors acknowledge the complexities of entering clinical trials. They are prepared to navigate the business landscape and the next steps required to bring their innovation to patients, with clinical trials anticipated in the coming years.